Theranostic agents for PSMA positive cancers
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNaga Vara Kishore Pillarsetty, Teja Muralidhar Kalidindi, Sang Gyu Lee, Steven M. Larson, Jason S. Lewis, Serge Lyashchenko, Eva Burnazi
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and methods of using the same in diagnostic imaging as well as radiation therapy.
Claims19
A compound of Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer thereof:
- wherein,
- X1 and X2 are independently selected from the group consisting of H, I, Br, At, a radioisotope of Br (Br*), a radioisotope of I (I*), and a radioisotope of At (At*), provided at least one of X1 and X2 is not H;
- and
- n is 1, 2, 3, or 4.
A kit comprising a compound of Formula II and an oxidant sufficient to activate iodide, bromide or astatide for labeling of the compound of Formula II, a stereoisomer thereof, or a salt of the compound or stereoisomer:
- wherein n is 1, 2, 3, or 4, wherein n is 3 and/or wherein the oxidant is chloramine T or 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril.
Dependencies are inferred from the claim text.